In addition, a phase I/II clinical study (NCT03211416) is evaluating the administration of sorafenib in combination with pembrolizumab (anti-PD-1) in metastatic HCC patients (Table S1). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.